Proteases and the biology of glioma invasion

Journal of Neuro-Oncology

Volumn 56, Issue 2, 2002, Pages 149-158

  Binder, Devin K ^a   Berger, Mitchel S ^a  

^a UCSF Medical Center at Parnassus   (United States)

Author keywords

Extracellular matrix; Gliomas; Growth factors; Invasion; Matrix metalloproteases; Tumor suppressor genes

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BATIMASTAT; CANCER GROWTH FACTOR; CYCLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE INHIBITOR; GROWTH FACTOR RECEPTOR; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PRINOMASTAT; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTROCYTOMA; CANCER GRADING; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CLINICAL TRIAL; DISSEMINATED CANCER; DRUG BIOAVAILABILITY; DRUG TARGETING; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GLIOMA; HEART DISEASE; HUMAN; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TUMOR SUPPRESSOR GENE;

CELL DIVISION; GENES, TUMOR SUPPRESSOR; GLIOMA; HUMANS; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; PROGNOSIS;

EID: 0036207326     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014566604005     Document Type: Review

References (103)

1. Glioblastoma and malignant astrocytoma
2. Brain tumor epidemiology, growth and invasion
3. Glioma invasion in the central nervous system
4. The in vitro motility of human gliomas increases with increasing grade of malignancy
5. Pathologic anatomy and CT correlations in the glioblastoma multiforme
6. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas
7. Malignant astrocytomas: Focal tumor recurrence after focal external beam radiation therapy
8. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms
9. Distribution of extracellular matrix proteins in primary human brain tumors: An immunohistochemical analysis
10. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors
11. Cathepsins B and L are markers for clinically invasive types of meningiomas
12. The matrix-degrading metalloproteinases
13. Matrix metalloproteinases
14. The family of matrix metalloproteinases
15. Cell-derived proteases and protease inhibitors as regulators of neurite outgrowth
16. Metastatic potential correlates with enzymatic degradation of basement membrane collagen
17. Biology and biochemistry of proteinases in tumor invasion
18. A matrix metalloproteinase expressed on the surface of invasive tumour cells
19. Contributions of tumor and stromal matrix metalloproteases to tumor progression, invasion and metastasis
20. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas
21. Mechanisms of glioma invasion: Role of matrix-metalloproteinases
22. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors
23. Metalloproteinase capable of destroying cultured brain tissue isolated from rat glioma cells
24. Glioblastoma infiltration into central nervous system tissue in vitro: Involvement of a metalloprotease
25. Serum proteolytic activity during the growth of C6 astrocytoma
26. Elevated levels of Mr 92,000 type IV collagenase in human brain tumors
27. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo
28. Role of plasminogen activator and of 92-kDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model
29. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro
30. Expression of 72 kDa type IV collagenase and invasion activity of human glioma cells
31. Glioma invasion in vitro: Regulation by matrix metalloprotease-2 and protein kinase C
32. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo
33. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis
34. Classification, grading, and patterns of spread of malignant gliomas
35. Patterns of tumor growth
36. White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues
37. Membrane-type 1 matrix metalloproteinase (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter
38. Growth factor control of extracellular proteolysis
39. TGF-beta 1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence
40. Epidermal growth factor stimulation of stromelysin mRNA in rat fibroblasts requires induction of proto-oncogenes c-fos and c-jun and activation of protein kinase C
41. Tissue inhibitors of metalloproteinases: Evolution, structure and function
42. cDNA cloning and expression of a metalloproteinase inhibitor related to tissue inhibitor of metalloproteinases
43. Protease inhibitors: Role and potential therapeutic use in human cancer
44. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases
45. Transfection of an invasive human astrocytoma cell line with a TIMP-1 cDNA: Modulation of astrocytoma invasive potential
46. Expression of tissue inhibitors of metalloproteinases: Negative regulators of human glioblastoma invasion in vivo
47. The molecular biology of brain tumors
48. Molecular pathogenesis of malignant gliomas
49. Cell cycle control and cancer
50. Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
51. Comparative study of p53 gene and protein alterations in human astrocytic tumors
52. Molecular genetics of radiographically defined de novo glioblastoma multiforme
53. P53 alterations and clinical outcome in low-grade astrocytomas
54. Alterations of the TP53 gene in human gliomas
55. Retinoblastoma gene deletions in human glioblastomas
56. Loss in expression of the retinoblastoma gene product in human gliomas is associated with advanced disease
57. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression
58. Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations
59. Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas
60. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression
61. Wild-type p53 gene transfer inhibits invasion and reduces matrix metalloproteinase-2 levels in p53-mutated human melanoma cells
62. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins
63. Cyclin-D1 protein oscillates and is essential for cell-cycle progression in human tumour cell lines
64. Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck
65. Over-expression of cyclin D1 induces glioma invasion by increasing matrix metalloproteinase activity and cell motility
66. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas
67. Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues
68. Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas
69. Endothelial cell hyperplasia in human glioblastoma: Coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation
70. Antoniades HN: Coexpression of platelet derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance
71. Platelet-derived growth factor and its receptors in human glioma tissue: Expression and messenger RNA and protein suggests the presence of autocrine and paracrine loops
72. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumors of glial origin
73. Amplified cellular oncogenes in neoplasms of the human central nervous system
74. Gene amplification in human gliomas
75. Structural alterations of the epidermal growth factor receptor gene in human gliomas
76. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification
77. Expression of activated epidermal growth factor receptors, ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens
78. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer
79. Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion
80. Protein kinase C and growth regulation of malignant gliomas
81. Protein kinase C (PKC) activity correlates with growth rate of gliomas. II: Effects of glioma mitogens and modulators of PKC
82. Antisense expression of protein kinase C alpha inhibits the growth and tumorigenicity of human glioblastoma cells
83. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
84. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
85. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody against epidermal growth factor receptor: A phase II trial
86. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1
87. Inhibitory effect of antisense epidermal growth factor RNA on the proliferation of rat C6 glioma cells in vitro and in vivo
88. The potential of protein kinase C as a target for anticancer treatment
89. Inhibition of protein kinase C by tamoxifen
90. The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: Preliminary results in a series of 'failed' patients
91. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen
92. Inhibition of phospholipase C-gamma1 activation blocks glioma cell motility and invasion of fetal rat brain aggregates
93. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice
94. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models
95. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts
96. Matrix metalloproteinase inhibitors: A novel class of anticancer agents
97. Synthetic matrix metalloproteinase inhibitors: From cancer models to cancer patients
98. Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro
99. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials
100. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340
101. Sublethal irradiation promotes migration and invasiveness of glioma cells: Implications for radiotherapy of human glioblastoma